Fibroblast growth factors (FGFs) signal in a paracrine or endocrine fashion to mediate a myriad of biological activities, ranging from issuing developmental cues, maintaining tissue homeostasis, and regulating metabolic processes. FGFs carry out their diverse functions by binding and dimerizing FGF receptors (FGFRs) in a heparan sulfate (HS) cofactor-or Klotho coreceptor-assisted manner. The accumulated wealth of structural and biophysical data in the past decade has transformed our understanding of the mechanism of FGF signaling in human health and development, and has provided novel concepts in receptor tyrosine kinase (RTK) signaling. Among these contributions are the elucidation of HS-assisted receptor dimerization, delineation of the molecular determinants of ligand-receptor specificity, tyrosine kinase regulation, receptor cis-autoinhibition, and tyrosine trans-autophosphorylation. These structural studies have also revealed how disease-associated mutations highjack the physiological mechanisms of FGFR regulation to contribute to human diseases. In this paper, we will discuss the structurally and biophysically derived mechanisms of FGF signaling, and how the insights gained may guide the development of therapies for treatment of a diverse array of human diseases.
Fibroblast growth factors (FGFs) signal in a paracrine or endocrine fashion to mediate a myriad of biological activities, ranging from issuing developmental cues, maintaining tissue homeostasis, and regulating metabolic processes. FGFs carry out their diverse functions by binding and dimerizing FGF receptors (FGFRs) in a heparan sulfate (HS) cofactor-or Klotho coreceptor-assisted manner. The accumulated wealth of structural and biophysical data in the past decade has transformed our understanding of the mechanism of FGF signaling in human health and development, and has provided novel concepts in receptor tyrosine kinase (RTK) signaling. Among these contributions are the elucidation of HS-assisted receptor dimerization, delineation of the molecular determinants of ligand-receptor specificity, tyrosine kinase regulation, receptor cis-autoinhibition, and tyrosine trans-autophosphorylation. These structural studies have also revealed how disease-associated mutations highjack the physiological mechanisms of FGFR regulation to contribute to human diseases. In this paper, we will discuss the structurally and biophysically derived mechanisms of FGF signaling, and how the insights gained may guide the development of therapies for treatment of a diverse array of human diseases. F ibroblast growth factor (FGF) signaling fulfills essential roles in metazoan development and metabolism. A wealth of literature has documented the requirement for FGF signaling in multiple processes during embryogenesis, including implantation (Feldman et al. 1995) , gastrulation (Sun et al. 1999) , somitogenesis (Dubrulle and Pourquie 2004; Wahl et al. 2007 ; Lee et al. 2009; Naiche et al. 2011; Niwa et al. 2011) , body plan formation (Martin 1998; Rodriguez Esteban et al. 1999; Tanaka et al. 2005; Mariani et al. 2008) , morphogenesis (Metzger et al. 2008; Makarenkova et al. 2009 ), and organogenesis (Goldfarb 1996; Kato and Sekine 1999; Sekine et al. 1999; Sun et al. 1999; Colvin et al. 2001; Serls et al. 2005; Vega-Hernandez et al. 2011) . Recent clinical and biochemical data have uncovered unexpected roles for FGF signaling in metabolic processes, including phosphate/vitamin D homeostasis (Consortium 2000; Razzaque and Lanske 2007; Nakatani et al. 2009; Gattineni et al. 2011; Kir et al. 2011) , cholesterol/ bile acid homeostasis (Yu et al. 2000a; Holt et al. 2003) , and glucose/lipid metabolism (Fu et al. 2004; Moyers et al. 2007 ). Highlighting its diverse biology, deranged FGF signaling contrib-utes to many human diseases, such as congenital craniosynostosis and dwarfism syndromes (Naski et al. 1996; Wilkie et al. 2002 Wilkie et al. , 2005 , Kallmann syndrome (Dode et al. 2003; Pitteloud et al. 2006a) , hearing loss (Tekin et al. 2007 (Tekin et al. , 2008 , and renal phosphate wasting disorders (Shimada et al. 2001; White et al. 2001) , as well as many acquired forms of cancers (Rand et al. 2005; Pollock et al. 2007; Gartside et al. 2009; di Martino et al. 2012) . Endocrine FGFs have also been implicated in the progression of acquired metabolic disorders, including chronic kidney disease (Fliser et al. 2007) , obesity (Inagaki et al. 2007; Moyers et al. 2007; Reinehr et al. 2012) , and insulin resistance (Fu et al. 2004; Chen et al. 2008b; Chateau et al. 2010; Huang et al. 2011) , giving rise to many opportunities for drug discovery in the field of FGF biology .
Based on sequence homology and phylogeny, the 18 mammalian FGFs are grouped into six subfamilies (Ornitz and Itoh 2001; Popovici et al. 2005; Itoh and Ornitz 2011) . Five of these subfamilies act in a paracrine fashion, namely, the FGF1 subfamily (FGF1 and FGF2), the FGF4 subfamily (FGF4, FGF5, and FGF6), the FGF7 subfamily (FGF3, FGF7, FGF10, and FGF22), the FGF8 subfamily (FGF8, FGF17, and FGF18), and the FGF9 subfamily (FGF9, FGF16, and FGF20). In contrast, the FGF19 subfamily (FGF19, FGF21, and FGF23) signals in an endocrine manner . FGFs exert their pleiotropic effects by binding and activating the FGF receptor (FGFR) subfamily of receptor tyrosine kinases that are coded by four genes (FGFR1, FGFR2, FGFR3, and FGFR4) in mammals (Johnson and Williams 1993; Mohammadi et al. 2005b ). The extracellular domain of FGFRs consists of three immunoglobulin (Ig)-like domains (D1, D2, and D3), and the intracellular domain harbors the conserved tyrosine kinase domain flanked by the flexible amino-terminal juxtamembrane linker and carboxy-terminal tail (Lee et al. 1989; Dionne et al. 1991; Givol and Yayon 1992) . A unique feature of FGFRs is the presence of a contiguous segment of glutamic and aspartic acids in the D1 -D2 linker, termed the acid box (AB). The two-membrane proximal D2 and D3 and the intervening D2 -D3 linker are necessary and sufficient for ligand binding/specificity (Dionne et al. 1990; Johnson et al. 1990) , whereas D1 and the D1 -D2 linker are implicated in receptor autoinhibition (Wang et al. 1995; Roghani and Moscatelli 2007; Kalinina et al. 2012) . Alternative splicing and translational initiation further diversify both ligands and receptors. The amino-terminal regions of FGF8 and FGF17 can be differentially spliced to yield FGF8a, FGF8b, FGF8e, FGF8f (Gemel et al. 1996; Blunt et al. 1997) , and FGF17a and FGF17b isoforms (Xu et al. 1999) , whereas cytosine-thymine-guanine (CTG)-mediated translational initiation gives rise to multiple high molecular weight isoforms of FGF2 and FGF3 (Florkiewicz and Sommer 1989; Prats et al. 1989; Acland et al. 1990 ). The tissue-specific alternative splicing in D3 of FGFR1, FGFR2, and FGFR3 yields "b" and "c" receptor isoforms which, along with their temporal and spatial expression patterns, is the major regulator of FGF-FGFR specificity/promiscuity (Orr-Urtreger et al. 1993; Ornitz et al. 1996; Zhang et al. 2006) . A large body of structural data on FGF-FGFR complexes has begun to reveal the intricate mechanisms by which different FGFs and FGFRs combine selectively to generate quantitatively and qualitatively different intracellular signals, culminating in distinct biological responses. In addition, these structural data have unveiled how pathogenic mutations hijack the normal physiological mechanisms of FGFR regulation to lead to pathogenesis. We will discuss the current state of the structural biology of the FGF-FGFR system, lessons learned from studying the mechanism of action of pathogenic mutations, and how the structural data are beginning to shape and advance the translational research.
STRUCTURE -FUNCTION RELATIONSHIP OF FGFs
FGFs range in size from 150 -300 amino acids (Basilico and Moscatelli 1992; Mohammadi et al. 2005b ). Crystal structures with at least one representative from each subfamily, namely FGF1 and FGF2 (Eriksson et al. 1991; Zhang et al. 1991; Zhu et al. 1991) , FGF4 (Bellosta et al. 2001) , FGF7 (Ye et al. 2001) , FGF8b , FGF9 , FGF10 (Yeh et al. 2003) , FGF19 (Harmer et al. 2004; Goetz et al. 2007 ), FGF20 (Kalinina et al. 2009 ), and FGF23 ) have been solved. In addition, crystal structures of FGF1, FGF2, FGF8b, and FGF10 in complex with their cognate receptor(s) have been solved, providing valuable insights into the structure-function relationships of the FGF family (Fig. 3) . These structures show that the FGF core homology domain (composed of 125 amino acids) adopts a conserved b-trefoil fold consisting of 12 antiparallel b strands (b1-b12) in paracrine FGFs (Mohammadi et al. 2005b) . Endocrine FGFs lack the b11 strand, and hence have an atypical trefoil fold Beenken and Mohammadi 2011) . The FGF trefoil core is flanked byamino-and carboxy-terminal regions that are highly variable in length and sequence among FGFs. These variable amino and carboxyl termini contribute key components in the regulation of distinct biological functions of different FGFs.
Paracrine FGFs exhibit moderate to high affinity for heparan sulfate (HS), a mandatory cofactor in paracrine FGF signaling (Rapraeger et al. 1991; Yayon et al. 1991; . HS is a heterogeneously sulfated glycosaminoglycan that is covalently linked to select serine residues in proteoglycans, such as membrane-anchored syndecans and glypicans and extracellular matrix (ECM) perlecans (Hacker et al. 2005; Iozzo et al. 2009 ). HS is a polymer of repeating disaccharide units consisting of glucuronic acid and amino acteylglucosamine linked through a-1,4-glycosidic bonds. HS is heterogeneously sulfated on the 2-O position of glucuronic and amino acids and the 6-O position of amino acteylglucosamine (Esko and Lindahl 2001) . Attributed to their high affinity for HS, paracrine FGFs can diffuse only a short distance away from their source of secretion, thus acting locally (Asada et al. 2009; Xu et al. 2012) . Unique among paracrine FGFs, the FGF9 subfamily undergoes reversible dimerization, whereby the dimer has higher affinity for HS. This provides an additional mechanism for acutely regulating the diffusion radius of the FGF9 subfamily of ligands, further reducing their signaling dimensionality Harada et al. 2009; Kalinina et al. 2009 ). The HS binding site of FGFs is composed of the b1-b2 loop and the extended b10 -b12 region, which provide solvent-exposed basic amino acids and backbone atoms for HS binding (Fig.  1B) . Because of the primary sequence variation of the HS binding site, each ligand has discrete affinity for HS, resulting in the formation of FGF-specific morphogenetic gradients that contribute to the distinct biology of FGF ). Despite primary sequence variations, however, the HS binding sites of paracrine FGFs adopt a common topology (Faham et al. 1998; Goetz et al. 2007 ). This is mainly because of the presence of the paracrineconserved GXXXXGXXS/T motif , referred to as the glycine box (Luo et al. 1998) . The backbone atoms of these two glycines engage in conserved hydrogen bonds with underlying b strands to facilitate the formation of the b11 strand (Fig. 1B) .
The topology of the HS binding region of the endocrine FGFs differs drastically from that of paracrine FGFs because of the lack of the paracrine-conserved glycine box and the truncated b10 -b12 region (Fig.  1B) . Importantly, the altered topologies of HS binding sites of the endocrine FGFs disallow the interaction of HS with the backbone atoms of the HS binding region. This manifests itself in major reductions in HS affinity of the endocrine FGFs (Yu et al. 2005; Goetz et al. 2007) , which allows these ligands to permeate freely through the HS-rich ECM and enter blood circulation (Fig. 1A,C) .
STRUCTURAL FEATURES OF FGFRs
Currently, there is no crystal structure of either the intact ectodomain or the D2 -D3 ligandbinding region of FGFR in the absence of the ligand. Nuclear magnetic resonance (NMR) solution studies of the D2 -D3 region show that D3 is an intrinsically flexible domain (Kalinina et al. 2012) . However, in the X-ray structures of ligand-bound D2 -D3, D3 adopts a stable Ig-like fold (Plotnikov et al. 1999 ). To date, there are crystal structures of eight different FGF-FGFR complexes that feature unique ligand -receptor combinations, including FGF1 with FGFR1c , FGFR2c (Stauber et al. 2000) , FGFR3c (Olsen et al. 2004 ), FGFR2b , FGF2 with FGFR1c (Plotnikov et al. 1999; Schlessinger et al. 2000) , FGFR2c , FGF8b with FGFR2c , and FGF10 with FGFR2b (Yeh et al. 2003) . In all these structures, the receptor adopts an extended conformation displaying significant differences in the relative orientation of D2 and D3 to one another, suggesting that the overall receptor orientation is dictated by ligand binding (Fig. 3) . This is harmonious with the fact that there are no intramolecular contacts between D2 and D3 that would constrain the relative disposition of the two domains in the absence of the ligand. As anticipated based on sequence homology (Bateman and Chothia 1995) , D1 and D2 adopt Ig folds that belong to the I set of the Ig superfamily (Plotnikov et al. 1999; Hung et al. 2005; Kiselyov et al. 2006) (Fig. 2A) . In contrast, D3 has an unusual Ig-fold in that the region between the bC 0 and bE strands (referred to as the bC 0 -bE loop) adopts a different conformation in different complexes, suggesting that it is highly mobile. In all but the FGF8b -FGFR2c structure, D3 lacks the analogous bD strand of the Ig-like domains D1 and D2. Notably, alternative splicing of D3 occurs at the junction between the bC 0 strand and the bC 0 -bE loop, diversifying the primary sequence of the loop (Johnson et al. 1991; Yeh et al. 2003) (Fig. 2A) . As we will discuss later, this, together with the inherent flexibility of the loop, plays a major role in determining ligand-binding specificity/promiscuity. The HS binding site of the receptor resides in D2 and is comprised of several surface-exposed residues emanating from the bB, bE, bD strands, the gA helix, and the loop between the bA and bA 0 strands of D2 . Unlike the FGF-HS interaction, only the side chains of D2 participate in HS coordination, which explains the significantly lower affinity of FGFRs for HS compared to that of FGFs (Powell et al. 2002; Ibrahimi et al. 2004c; Asada et al. 2009; Trueb 2011) .
The bottom edge of D2, the D2 -D3 linker, and the top portion of D3 compose the ligandbinding pocket (Plotnikov et al. 1999) (Fig 2A) . The FGF straddles D3 via the bottom end of the trefoil (the top end being the HS binding site). The bB 0 -bC and bF-bG loops in D3 are engulfed in a depression formed between the b1, b2, b4, b5, b8, and b9 strands and the intervening loops, whereas the D2 -D3 linker cooperates with D3 to further fix the ligand in its observed position (Fig. 2C ). The bA 0 and bF strands at the bottom edge of D2 sharply engage the b1 through b2 strands, the b3-b4 loop, and b9 and b12 of the ligand ( Fig. 2A) .
THE FGF -FGFR INTERFACE Conserved Ligand-Receptor Contacts
Each subdomain makes several highly conserved contacts with the ligand, unambiguously demonstrating that the D2 -D3 fragment is the minimal binding region of FGFs (Stauber et al. 2000; Olsen et al. 2004; Mohammadi et al. 2005b) . At the FGF-D2 interface, two conserved tyrosine residues, one from the b1 strand and another from the b8-b9 loop, along with highly conserved proline in the b12 strand of the ligand engage in hydrophobic and hydrogen-bonding interactions with conserved residues on the bA 0 and bG strands in D2 (Fig. 2B) . The interface between FGF and the D2 -D3 linker is by far the most conserved residue. Here, an invariant arginine from the D2 -D3 linker region makes three hydrogen bonds with a side chain of a residue in b9 and a backbone of the b8-b9 loop in the ligand (Fig. 2C ). The b9 residue is an asparagine in all FGFs, with the exception of the FGF8 subfamily, which has a threonine instead. Notably the D2 -D3 linker arginine is also engaged in intramolecular hydrogen bonding with a conserved aspartic acid in the bB 0 -bC loop of D3. This primes the arginine for FGF recognition, thus minimizing the entropic penalty associated with ligand binding. The focal role of these hydrogen bonds in providing general FGF-FGFR affinity is evidenced by the fact that fibroblast homologous factors (FHFs) contain a valine in the equivalent position of b9 asparagine, which hinders them from binding/activating FGFRs (Goldfarb 1996; Olsen et al. 2003; Goetz et al. 2009; Wang et al. 2012) . Mutation of the D2 -D3 linker arginine to glutamine leads to a loss of function in the Kallmann syndrome (Dode et al. 2003; Pitteloud et al. 2006a,b) , further highlighting the importance of these conserved hydrogen bonds in FGF-FGFR binding. The FGF-D3 interface harbors two highly conserved contacts. Here the backbone atoms of the bB 0 -bC loop are engaged in three strong hydrogen bonds with an arginine from b1 and glutamic acid from b8 of the ligand (Fig. 2C) . Together, the aforementioned contacts provide general FGF-FGFR binding affinity, whereas specificity is primarily decided by divergent contacts at the FGF-D3.
ALTERNATIVE SPLICING IN D3 IS A MAIN MECHANISM IN REGULATION OF FGF -FGFR SPECIFICITY
In FGFR1-3, two alternative exons ("b" and "c") code for the second half of D3 (Johnson et al. 1991; Miki et al. 1992; Yayon et al. 1992) that are spliced in tissue-specific fashion (OrrUrtreger et al. 1993; Wuechner et al. 1996; Beer et al. 2000) . Generally, the b-splice variants are expressed in the epithelial tissue, whereas the csplice isoforms are expressed in the mesenchymal tissue (Orr-Urtreger et al. 1993; McEwen and Ornitz 1997) . Paracrine FGFs also show tissue-specific expression patterns with ligands for FGFRb isoforms being expressed in mesenchyme, and ligands for FGFRc isoforms expressed in epithelium (Finch et al. 1989) . This results in an epithelial -mesenchymal FGF signaling loop that is crucial for tissue homeostasis and organogenesis (McIntosh et al. 2000; Itoh and Ornitz 2011) , as evidenced by the fact that derangements of this signaling loop contribute to human skeletal disorders and cancer Mohammadi 2009, 2011) . The tissue-specific alternative splicing in D3 is the chief mechanism in the regulation of FGF-FGFR binding specificity Ornitz et al. 1996; Zhang et al. 2006 ). Crystallographic studies of eight different FGF-FGFR complexes have revealed that this alternative splicing controls FGF-FGFR binding specificity/promiscuity by altering the composition of FGF binding sites in D3, including the bC 0 -bE and bF-bG loops. Moreover, the bC 0 -bE loop is inherently flexible, and is capable of adapting uniquely to each ligand. The regions of FGFs that engage the alternatively spliced half of D3, in particular, the amino-terminal region of ligands, is divergent in the primary sequence. These structural data flag the FGF-D3 interface as the key mediator of FGF-FGFR binding specificity/promiscuity. The current structural data on FGF-FGFR complexes have disclosed two distinct modes by which contacts at the FGF-D3 interface mediate FGF-FGFR binding specificity.
GENERAL MODE OF FGF -FGFR SPECIFICITY
The hallmark of the general mode, observed in the FGF1-, FGF2-, and FGF10-receptor complexes, is a cleft in D3 that forms between bB 0 -bC and the alternatively spliced bC 0 -bE on ligand binding. This cleft is induced by hydrophobic contacts between residues from the b7 and b8 loops and the b5 strand in the FGF core, and a hydrophobic residue at the apex of the alternatively spliced bC 0 -bE of the receptor (Fig. 3A-C) . Residues from the b4, b5 strands and the intervening loop as well as the aminoterminal tail of the ligand engage the bC 0 -bE loop, further stabilizing the cleft. The bF-bG loop, which is also alternatively spliced, engages residues from the b4-b5 loop and the b8 strand.
FGF7 Subfamily
FGF7 subfamily members are secreted by the mesenchyme and act exclusively on the FGFR2b resident in the epithelial tissue to constitute the mesenchymal-to-epithelial arm of the signaling loop (Mason et al. 1994 ). The FGF10 -FGFR2b structure (Yeh et al. 2003) shows that F146, Y131, and A122 in FGF10 form a hydrophobic surface that tethers Ile-317 from the alternatively spliced loop promoting formation of the D3 cleft (Fig 3B) . According to the structure, the FGF7 subfamily's preference for FGFR2b can be traced to the highly specific hydrogen bonds between Asp-76, a unique amino-terminal residue in the FGF7 subfamily, and Ser-315 from the alternatively spliced bC 0 -bE loop in the D3 cleft. A p-cation interaction between Y345 in the bF-bG (a residue unique to b-splice isoforms of receptors) and R155 in the b8 strand of FGF10 further reinforces the specificity (Fig.  3A,B) . Interestingly, the substitution of the conserved tyrosine in the b1 strand for phenylalanine in the FGF7 subfamily acts in concert with the above-mentioned specific FGF-D3 contacts to further narrow the specificity of the FGF7 subfamily for FGFR2b. This Y!F substitution disables this subfamily form hydrogen bonding with D2 (Fig. 2B) , thus minimizing the contribution of D2 in providing ligand-binding affinity. By primarily relying on the alternatively spliced loops of D3 of the receptor to attain specificity and affinity, the FGF7 subfamily is solely able to bind and activate FGFR2b. In the absence of these hydrogen bonds that impose constrains on the orientation of D3, D2 is observed to rotate about the D2 -D3 linker, resulting in a distinct orientation of the HS binding site in D2, relative to the ligand. This structural change has been postulated to play a role in determining the HS selectivity of the FGF7 subfamily FGFR2b complexes (Mohammadi et al. 2005a ).
FGF1 Subfamily
Unlike the FGF7 subfamily, whose members share a common receptor specificity profile, the members of the FGF1 subfamily, namely FGF1 and FGF2, have a distinct receptor binding specificity/promiscuity profile (Ibrahimi et al. 2004a,b) . Both FGF1 and FGF2 are promiscuous and can bind more than one FGFR isoform.
Molecular Mechanisms of FGF Signaling
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Crystal structures of FGF2 with both of its cognate receptors have been solved (Plotnikov et al. 1999 , revealing the molecular basis for the FGFR binding specificity/promiscuity of FGF2. Reminiscent of the FGF10 -FGFR2b structure, a valine/isoleucine at the apex of the bC 0 -bE loop makes hydrophobic contacts with Y73 (from the b6 strand) and V88 and F93 (from the b7-b8 loop), resulting in the formation of the D3 cleft (Fig. 3C) . The specificity/ promiscuity of FGF2 can be traced mostly to specific hydrogen bonds between Q56 from the b4 strand of FGF2 and D321 in the D3 cleft.
F17 from the amino terminus is immersed in a hydrophobic pocket created by I288, P286, and V280 in the D3 cleft, while also engaging in hydrogen-aromatic interactions with D321 (Fig. 3C) . The bC 0 -bE loop of "b-"splice isoforms would not be able to endorse these specific contacts.
The crystal structure of FGF1 in complex with four of its cognate FGFRs, namely, FGFR1c ), FGFR2c (Stauber et al. 2000) , FGFR3c (Olsen et al. 2004) , and FGFR2b , have been solved. Analysis of these four FGF1 -FGFR structures show that the promiscuity of FGF1 can be traced to the unusual ability of FGF1 to adapt to the alternatively spliced bC 0 -bE loop on the receptor. The versatility in the interactions of FGF1 with the bC 0 -bE loop manifests itself in the observed divergent conformation of the bC 0 -bE loop in the four FGF1 -FGFR structures. The FGF1-FGFR1c, FGF1 -FGFR2c, and FGF1 -FGFR2b complexes all feature the characteristic D3 cleft, whereas the FGF1-FGFR3c structure lacks it. Three amino-terminal residues of FGF1, namely, F16, N22, and Y23 FGF1 make variable interactions with D3, depending on which receptor they interact with . Replacing the corresponding three amino-terminal residues in FGF2 with that of FGF1 bestows on FGF2 the ability to bind to the FGFR2b isoform, thus verifying the structural data. As a corollary to FGF10 specificity, subtle changes at the FGF1 -D2 contacts augment the promiscuity of FGF1. Notably, FGF1 has an L135 instead of an M142 in FGF2 at the FGF-D2 interface, which enables FGF1 to engage in stronger hydrophobic contacts with D2, thereby gaining more affinity through D2 contacts. This enhances the promiscuity of FGF1 as it reduces the dependency of FGF1 on D3 for receptor binding.
Structural and biochemical studies of pathogenic mutations affecting the extracellular domain of FGFRs strongly support the regulatory mechanisms of FGF-FGFR binding specificity/ promiscuity deduced from FGF-FGFR crystal structures (Wilkie 2005) . For example, the S252W and P253R mutations in the D2 -D3 linker region of FGFR2, responsible for the Apert syndrome (Wilkie et al. 1995) , introduce additional conserved contacts with FGFs that result in a generalized increase in affinity of the receptor for all FGFs, thus minimizing the reliance of FGF on specific contacts with D3 for receptor binding (Anderson et al. 1998; Ibrahimi et al. 2001; Yu and Ornitz 2001; Glaser et al. 2003; Yoon et al. 2009 ). This enables the mesenchymallyexpressed diseased FGFR2c to illegitimately bind and become activated in an autocrine fashion by mesenchymmal FGF10, thereby short-circuiting the epithelial-to-mesenchyme signaling polarity (Yu et al. 2000b) . Likewise, structural studies of the D321A mutation, which maps onto the bC 0 -bE loop of FGFR2c, show that this mutation removes the electrostatic repulsion and steric conflict that prohibits binding of FGFR2c to FGF10, thereby enabling the illegitimate activation of the "diseased" receptor by FGF10 in the mesenchyme (Ibrahimi et al. 2004a ).
FGF8 SUBFAMILY-SPECIFIC MODE OF FGF -FGFR SPECIFICITY
FGF8 subfamily members are expressed in the epithelial tissue and activate the c-splice isoforms of FGFRs that reside in the underlying mesenchyme to mediate the epithelial-to-mesenchymal arm of the signaling loop (Blunt et al. 1997) . Members of the FGF8 subfamily share an overlapping receptor binding specificity/ promiscuity profile and bind redundantly to FGFR1c -3c and FGFR4 . The FGF8 subfamily uses a different mode to attain FGFR binding specificity that can be traced to unique prestructured amino termini of this subfamily. In contrast to FGF1, FGF2, and FGF10, which have flexible amino termini, the amino terminus of the FGF8 subfamily adopts a rigid conformation that enables it to wrap around D3 and engage the opposite face of D3 (Fig. 3D) . Structural analysis shows that in FGF1, FGF2, and FGF10, the first occurrence of a glycine or proline aborts the b1 strand amino terminally, while also causing the amino terminus to turn away from D3. In the FGF8 subfamily, however, the absence of an amino-terminal proline/glycine allows the b1 strand to continue stranding with b4, which places the amino terminus in an opposite orientation compared to FGF1, FGF2, and FGF10 ). FGF8b residues F32 -S40 form a g helix, which is linked to the b1 strand via an extended loop. The conformation of this loop is stabilized by intramolecular contacts with the FGF8 core. F32, V36 from the gN helix, along with F92 from the b4-b5 loop, engage an extended hydrophobic groove formed by I291 (bC), L309 (bC 0 ), L343 (bF), I350 (bG), and F352 (bG) at the bottom sheet of D3 (Fig. 3D) . The bF and bG strands reside in the alternatively spliced half of D3, and the replacement of L343 and I350 by polar residues in b isoforms of FGFR1 -3 and FGFR4 explain the subfamily's specificity for FGFRc isoforms and FGFR4 ). Additional specificity is mediated by the FGF8-specific serine insertion in the b4-b5 loop, which forms a unique network of hydrogen bonds with the backbone atoms of the alternatively spliced bB 0 -bC and bF-bG loops.
The bC 0 -bE loop conformation is totally rearranged to make room for the unique FGF8 amino terminus. In fact, a section of this loop forms the canonical Ig-folded bD strand that is connected to bE through a short loop. All the loops connecting the strands of the top sheet localize on one side, and, as a result, the FGF8b-FGFR2c structure lacks the D3 cleft. The unique mode of FGF8b -FGFR2c binding induces a unique D3 rotation that pivots about the D2 -D3 linker. Modeling studies show that the membrane insertion points of receptor monomers in the FGF8b -FGFR2c dimer would be closer by 15 Å vis-à-vis the FGF2 -FGFR2c dimer. These topological differences have been postulated to contribute to the distinct signaling capacity by different FGFs ). The L341S loss-of-function mutation in FGF-R1, which is responsible for the Kallmann syndrome, maps to the D3 groove that the FGF8 subfamily engages (Dode et al. 2003; Pitteloud et al. 2006a; Falardeau et al. 2008 ). The substitution of leucine for the polar serine in this hydrophobic groove severely impairs the FGF8b binding, thus implicating the FGF8 subfamily in the etiology of the Kallmann syndrome. Indeed, subsequent genetic screening of a cohort of patients led to the identification of loss-offunction mutations in FGF8 and FGF17 (Falardeau et al. 2008; Trarbach et al. 2010; McCabe et al. 2011) .
In summary, contacts between FGF and alternatively spliced regions in D3 dictate FGF-FGFR specificity and promiscuity, whereas contacts between FGF and D2 and the D2 -D3 linker serve primarily to provide basal ligand-binding affinity. Importantly, differences in the contacts between FGF and D2 and/or D2 -D3 contacts can enhance specificity/promiscuity of FGFs by modifying the basal FGF-FGFR affinity. The fidelity of FGF-FGFR binding specificity/ promiscuity combined with ligand-dependent differences in receptor orientation would allow for the precise regulation of FGF-induced signaling.
HS-ASSISTED PARACRINE FGF -FGFR DIMERIZATION
HS is a mandatory cofactor in paracrine FGF signaling (Imamura and Mitsui 1987; Rapraeger et al. 1991; Yayon et al. 1991; Olwin and Rapraeger 1992; , as documented by the fact that mice and flies with defects in components of FGF signaling or HS biosynthetic enzymes share overlapping phenotypes (Lin et al. 1999; Inatani et al. 2003) . Structural data have shown that HS promotes the formation of a symmetric 2:2:2 dimer between FGF, FGFR, and HS, which is required for signal transmission across the plasma membrane . In the dimeric complex, FGFs engage D2, D3, and the D2 -D3 linker of their primary receptor (as discussed in depth above). In addition, residues from the b8-b9 and b11-b12 loops of FGFs interact with the bC 0 -bD and bE-bF loops in D2 of the neighboring (secondary) receptor (Fig. 4A) . Notably, the primary sequence of the b11 -b12 loop shows considerable variation among FGFs, indicating that additional FGF-FGFR signaling specificity may be achieved on receptor dimerization. The dimer interface is further fortified by the direct interactions between FGFRs mediated via the bottom end of their D2 domains ( Fig. 2A, B) . A 2:2:1 FGF-FGFR-HS asymmetric model has also been proposed (Pellegrini et al. 2000) ; however, analysis of the mechanism of action of pathogenic mutations has lent unbiased support for the symmetric mode of dimerization (Mohammadi et al. 2005a ). For example, the A172F gain-of-function mutation that is implicated in the Pfeifer syndrome maps to the D2 -D2 receptor interface that has been shown to cause gain of function by facilitating ligand-dependent FGFR dimerization .
The HS binding sites of the ligands and receptors are adjacent to one other, forming a continuous basic canyon on the membrane distal end of the dimer. The HS binding residues of FGFs and FGFRs act in concert to recruit two HS molecules in a symmetric fashion (Fig. 4A) . Each HS oligosaccharide makes a total of 30 hydrogen bonds with a single FGF and both receptor D2 domains . Primary sequence differences at the HS binding sites of FGFs and FGFRs are proposed to lead to the formation of distinctly charged canyons destined to bind tissue-specific HS molecules (Mohammadi et al. 2005a; Zhang et al. 2009 ). Notably, the primary and secondary FGF-FGFR binding sites on D2, the direct FGFR-FGFR binding site, and the HS binding site are adjacent to each other, indicating that HS-mediated The two Klotho (KL) domains, shown in two shades of gray, were modeled using the crystal structure of myrosinase (PDB: 1E6S). The carboxy tail of FGF23 is also modeled to show that it engages a composite site created at the FGFR-Klotho interface.
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Cite this article as Cold Spring Harb Perspect Biol 2013;5:a015958 dimerization is a cooperative process (Fig. 4A , middle and bottom panels). By engaging ligand and receptors in the dimer, HS promotes the kinetics and thermodynamics of FGF-FGFR binding and dimerization, allowing for the transmission of a sustained and robust intracellular signal as opposed to the transient downstream signaling that is observed in HS-deficient cells (Yayon et al. 1991; Nugent and Edelman 1992; Mathieu et al. 1995; Delehedde et al. 2000) .
KLOTHO CORECEPTOR-DEPENDENT ENDOCRINE FGF SIGNALING
In addition to exhibiting a negligible HS binding affinity (Fig. 1C) , the endocrine FGFs also have poor affinity for their cognate FGFRs (Goetz et al. 2012b) . Modeling studies show key residues at their predicted receptor binding site of endocrine FGFs are substituted for residues that are suboptimal for receptor binding ) (Fig. 1B) . For example, substitution of the conserved arginine in the b1 strand and glutamic acid in the b8 strand with glycine and histidine, respectively, in FGF23 should cause a major reduction in receptor binding affinity of this ligand. As discussed earlier, each of these two residues make conserved hydrogen bonds with D3 to provide general receptor binding affinity (Fig. 2B,C) . The poor HS binding affinity, along with negligible FGFR binding affinity renders HS ineffective in promoting endocrine FGF-FGFR binding and dimerization . Instead, these ligands must rely on a/b Klotho coreceptors to signal (Urakawa et al. 2006; Kurosu et al. 2007; Ogawa et al. 2007; Kharitonenkov et al. 2008; Suzuki et al. 2008; Kuro-o 2012) . Klotho coreceptors are single-pass transmembrane proteins whose ectodomain consists of tandem KL domains, which are homologous to b-glucosidases (Kuro-o et al. 1997; Ito et al. 2000) . The Klotho coreceptors have been shown to associate constitutively with the c-splice isoforms of FGFR1 -3 and FGFR4 to promote binding and dimerization of endocrine FGF-FGFR complexes (Kurosu et al. 2006 (Kurosu et al. , 2007 Goetz et al. 2012a ). The Klotho dependency confines the target tissue specificity of endocrine FGFs to those that express a Klotho and b Klotho (Wu et al. 2007; Kurosu and Kuro-o 2008) . Signaling specificity is further reinforced by the inherent specificity of FGF19 subfamily members for FGFRs (Goetz et al. 2012a ). For example, FGF21 primarily activates the FGFR1c-b Klotho complex (Yie et al. 2012) , whereas FGF19 is able to activate both FGFR1c -b Klotho as well as FGFR4 -b Klotho. FGF23, on the other hand, binds promiscuously to FGFR1c-a Klotho, FGFR3c-a Klotho, and FGFR4-a Klotho (Yu et al. 2005; Goetz et al. 2012a) . Although the structural basis for ternary complex formation remains to be elucidated, biochemical studies have already provided significant insights into the molecular interactions between the components in the ternary complex (Fig. 4B) . These studies have shown that the a Klotho and b Klotho coreceptors employ two different mechanisms to promote ternary complex formation. a Klotho combines with FGFR1c to create a de novo site for the FGF23 carboxy tail, whereas b Klotho uses two distinct sites to bind independently to the FGFR and to either the FGF19 or FGF21 carboxy tail (Wu et al. 2008; Goetz et al. 2012a) . Consistent with the key role of the carboxy tail of FGF23 in signaling, the biological activity of FGF23 is downregulated by a naturally occurring proteolytic cleavage at an RXXR motif following the b-trefoil core (Shimada et al. 2001) . Interestingly, the proteolytically cleaved carboxy tail can competitively inhibit binding of native FGF23 to the FGFR1c -a Klotho complex (Goetz et al. 2010 (Goetz et al. , 2012a , indicating that this cleavage acts at two levels to inhibit FGF23 signaling: by inactivating FGF23 as well as by generating an endogenous inhibitor of FGF23 signaling. Pathogenic mutations of the RXXR motif abrogate proteolytic cleavage of the ligand (Shimada et al. 2002) and elevate the serum concentration of fulllength bioactive FGF23, which accelerates phosphate excretion in the kidney and results in autosomal dominant hypophosphatemic rickets (ADHR) . Recent biochemical data show that the mutation of residues that comprises the D3 hydrophobic groove in FGFRc isoforms and FGFR4, which mediates binding of the FGF8 subfamily, also abolishes Klotho binding (Goetz et al. 2012a) . Consistent with the overlap between FGF8 and Klotho binding sites on FGFR, the association of the Klotho coreceptor with FGFRs retards the ability of these receptors to respond to FGF8, indicating that endocrine and paracrine FGF signaling impact each other.
The insights gained into the mechanism of endocrine FGF signaling are already being exploited to develop agonists and antagonists of the endocrine FGF system for treating metabolic diseases, including diabetes, obesity, and disorders associated with perturbed phosphate and bile acid homeostasis (Goetz et al. 2010) . For example, a novel FGF21 agonist has been engineered by knocking out the HS binding affinity of FGF2 and swapping its carboxy-terminal tail with that of FGF21 or FGF19 (Goetz et al. 2012b ). This engineered FGF21 agonist is superior to native FGF21 in its insulin-sensitizing potential and is currently being evaluated in a mouse model for obesity. Using the same approach, FGF2 was converted into an FGF23 agonist, which may be used to treat patients with familial tumoral calcinosis, an inherited disorder, associated with loss-of-function mutations in FGF23 (Goetz et al. 2012b) . Conversely, the carboxy-terminal tail of FGF23 is being developed for treatment of renal phosphate wasting disorders, and possibly for combating the cardiovascular morbidity factor in chronic kidney disease that has been shown to be caused by elevated FGF23 serum levels (Goetz et al. 2010) .
ALTERNATIVE SPLICING OF D1 AND D1-D2 LINKER CONTROLS RECEPTOR AUTOINHIBITION
In FGFR1 -3, a second major alternative splicing event (involving exons encoding D1 and the AB-containing D1 -D2 linker regions) generates receptor isoforms lacking D1, the D1 -D2 linker, or both (Johnson et al. 1991; Givol and Yayon 1992; Hou et al. 1992; Xu et al. 1992; Shimizu et al. 2001) . The loss of D1 and the D1 -D2 linker enhances the affinity of FGFR for both HS and FGF, indicating that they play an autoinhibitory role in FGFR regulation (Wang et al. 1995; Roghani and Moscatelli 2007) . The molecular basis by which these regions exert receptor autoinhibition has been interrogated using solution NMR and surface plasmon resonance (SPR) spectroscopies (Kalinina et al. 2012) . The data show that the negatively charged AB subregion of the linker electrostatically engages the positively charged HS binding site on D2 in cis, thereby directly suppressing the HS affinity of the receptor (illustrated in Fig. 2A) . Because of the close proximity of the HS binding site to the primary and secondary ligand-binding sites, as well as the direct receptor-receptor binding sites on D2, the cis electrostatic AB:HS interactions also sterically autoinhibits FGF-FGFR binding and dimerization. Consistent with the AB subregion playing a key role in FGFR autoinhibition, the amino acid sequence of the AB subregion is strongly conserved among FGFR orthologs (Kalinina et al. 2012) .
MECHANISM OF FGFR KINASE REGULATION
HS or Klotho-dependent FGF-FGFR dimerization juxtaposes the cytoplasmic kinase domains, providing them with sufficient opportunity to trans-phosphorylate each other on specific tyrosine residues. A-loop tyrosine phosphorylation leads to a local rearrangement of the A loop into its active state, which in turn stabilizes the active conformation of the kinase globally and culminates in the upregulation of the intrinsic kinase activity (Hubbard 1999) . Secondary phosphorylation events on tyrosines in the JM ( juxtamembrane), kinase insert, and carboxy-tail regions are then ensued, providing docking sites for SH2-containing downstream signaling substrates, such as PLCg and CrkL (Eswarakumar et al. 2005; Seo et al. 2009 ). Crystallographic studies of FGFR kinases have afforded major insights into the molecular mechanisms of FGFR kinase regulation and deregulation in pathological states. The crystal structures of the FGFR1 kinase (FGFR1K) (Mohammadi et al. 1996; Bae et al. 2010 ) and FGFR2K (Chen et al. 2007 ) have been solved in both their unphosphorylated (low activity) and A-loop tyrosine phosphorylated (activated) states. Reminiscent of all cur-
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Cite this article as Cold Spring Harb Perspect Biol 2013;5:a015958 rently solved A-loop phosphorylated RTK kinase domains, including IRK (Hubbard 1997) , IGF1R (Favelyukis et al. 2001; Pautsch et al. 2001) , and MUSK (Bergamin et al. 2010) , the phosphate moiety of A-loop tyrosine ( pY654 in FGFRK1 and pY657 in FGFRK2) engages in two hydrogen bonds with an RTK-invariant arginine in the first half of the to stabilize the active conformation of the A-loop (Chen et al. 2007; Bae et al. 2010) (Fig. 5C,D) . This in turn triggers a more intimate interaction between the amino lobe and the carboxy lobe of kinase, optimally aligning residues from the A-loop, the catalytic loop, and the aC-helix to catalyze phosphotransfer reactions (Fig. 5D) .
In sharp contrast to other unphosphorylated RTKs, in which the ATP and substrate binding pockets are occluded in cis by the kinase A-loop or JM region, these sites remain accessible in FGFRKs, although the conformation of the carboxyl-terminal end of the A-loop is not optimal for substrate binding (Mohammadi et al. 1996) . A crystallographic analysis of FGFR2Ks harboring pathogenic gain-of-function mutations, responsible for craniosynostosis syndromes and cancers, has proved to be instrumental in unraveling the molecular mechanism of FGFRK autoinhibition (Chen et al. 2007) . A comparison of these unphosphorylated "diseased" FGFR2Ks with the wild-type unphosphorylated and A-loop phosphorylated FGFRKs shows that kinase autoinhibition is controlled at the level of protein dynamics. Specifically, a network of hydrogen bonds mediated by a triad of residues from the kinase hinge (E565), the aCb4 loop (N549), and the b8 strand (K641), are engaged in an autoinhibitory network of hydrogen bonds (termed "molecular brake") at the kinase-hinge region that restricts the transition of the kinase into the active state, thus stabilizing the low activity state (Chen et al. 2007 ) (Fig. 5A,B) . A-loop tyrosine phosphorylation or pathogenic gain-of-function mutations disengage this molecular break either directly or indirectly through allosteric communication between the A-loop and kinase hinge, thereby stabilizing the active state (Chen et al. 2007 ). The constituents of this molecular brake are conserved in other RTKs, including PDGFR, CSFLR, and KIT, and indicate that kinase regulation by a molecular brake may also apply to other RTKs. Loss-of-function mutations in the tyrosine kinase domains of FGFRs are also implicated in human diseases, such as Kallmann syndrome, lacrimo-auriculo-dento-digital (LADD) syndrome, and cleft lip and palate. The crystal structure of FGFR2K, containing the A628T mutation responsible for LADD syndrome shows that the introduction of the polar and bulkier threonine sterically hinders formation of hydrogen bonds between Arg630 and Asp626 in the catalytic loop, thus hampering substrate tyrosine binding and phosphate-transfer reaction (Lew et al. 2007 ).
STRUCTURAL BASIS FOR FGFR KINASE TRANS-AUTOPHOSPHORYLATION
As introduced earlier, tyrosine trans-autophosphorylation fulfills two key roles in RTK signaling: (1) the upregulation of kinase activity, and (2) the generation of docking sites for downstream signaling proteins (Lemmon and Schlessinger 2010) . Hence, elucidation of the structural basis for trans-phosphorylation is essential for grasping the mechanism of RTK signal transduction in physiological and pathological states and for identifying new strategies for targeted drug discovery. Two recent studies have captured snapshots of FGFR1 and FGFR2 kinases caught in the act of trans-phosphorylation (Chen et al. 2008a; Bae et al. 2010) . One kinase acts as the enzyme whereas the other kinase offers a phosphorylatable tyrosine from the kinase insert (Y583F in FGFR1) (Fig. 6B) or the carboxy-tail region (Y769 in FGFR2) (Chen et al. 2008a) (Fig.  6A) . The structural data show that tyrosine transphosphorylation entails both a substantial degree of sequence specificity and structural complementarities. Both trans-phosphorylation complexes are asymmetric, whereby the carboxy lobe of the "substrate" engages both the amino lobe and carboxy lobe of the enzyme, burying a 1650 Å 2 (kinase-insert tyrosine trans-phosphorylation complex) and a 1850 Å 2 (carboxy-tail tyrosine phosphorylation complex) solvent-exposed surface area. The enzyme-substrate interface can be roughly divided into a proximal (vicinity of the catalytic cleft) and a distal (remote from the catalytic cleft) site (Fig. 6A,B) . At the proximal interface, the phosphorylatable tyrosine and its immediate surrounding sequences from the substrate engage the catalytic cleft of the enzyme, whereas in the distal interface, the carboxy-lobe regions of the substrate engage the amino lobe of the enzyme remote from the enzyme catalytic cleft.
The structural mode by which the enzyme and the substrate embrace each other is very different between these two trans-phosphorylation complexes. Importantly, the kinase-insert tyrosine and the carboxy-tail tyrosine of the substrate dock into the active site of the enzyme from the opposite direction (Fig. 6A,B) . The overall topology of the carboxy-tail tyrosine trans-phosphorylation complex is dictated by the latching of the carboxyl-terminal end (negative pole) of the aI helix of the substrate onto the amino-terminal end ( positive pole) of the aG helix in the substrate at the proximal interface. This interaction assists Y769 (P-0) and its surrounding P-4 (T765) to P þ 3 (L772) residues to optimallyengage the active site and the P þ 1 pocket of the enzyme to mediate the proximal specificity. Prominent contacts at the prox-imal site include the salt bridge between E767 (P-2) of the substrate with R573 of the enzyme, hydrogen bonds of T765 (P-4) and N766 (P-3) with the aG helix of the enzyme, and hydrophobic contacts of L770 (P þ 1) and L772 (P þ 3) with a P þ 1 pocket (Fig. 6A, lower panel) . Specificity is augmented by specific contacts at the distal interface between the carboxy lobe of the substrate and the nucleotide-binding loop in the amino lobe of the enzyme. Prominent contacts at the distal site include perpendicular aromatic interactions between F600 of substrate and F492 of enzyme, and hydrogen bonds between N730 of substrate and backbone carbonyl oxygens of the nucleotide binding loop in the enzyme (Chen et al. 2008a) .
In contrast, the enzyme -substrate relationship in the kinase-insert trans-phosphorylation complex is determined by contacts between the carboxy-lobe of substrate and the amino-lobe of enzyme at the distal site (Bae et al. 2010) . Aside from the hydrogen bonds between R577 (from the amino-terminal end of the kinase insert) and backbone carbonyl oxygen atoms in the b3-aC loop, all the remaining interactions at this distal contact site are of van der Waals nature. Interestingly, as in the carboxy-tail tyrosine trans-phosphorylation complex, the nucleotide binding loop of the enzyme partakes in the distal site, indicating that this loop, in addition to coordinating ATP, may also participate in substrate recognition. At the proximal site, the pseudosubstrate Phe583 (Tyr583) occupies a very similar position in the catalytic pocket of the enzyme-acting kinase, even though phenylalanine is not in position to form hydrogen bonds with the catalytic base D623 and R627 (Fig. 6B) . Akin to the carboxy-tail tyrosine trans-phosphorylation complex, residues P-0 to P þ 3 form an antiparallel strand with b10 in the Aloop. Compared to the carboxy-tail tyrosine trans-phosphorylation complex, there are significantly fewer interactions at the proximal site in the FGFR1 kinase-insert trans-phosphorylation complex. In fact the hydrophobic P þ 1 pocket remains unengaged in this complex. Overall, the enzyme interface in the kinase-insert trans-phosphorylation complex contains fewer contacts and possesses lower shape complementarity than in the carboxy-tail tyrosine trans-phosphorylation complex (0.62 vs. 0.72). These differences are consistent with the kinase autophosphorylation data showing that phosphorylation of carboxy-tail tyrosine precedes that of kinase-insert tyrosine (Furdui et al. 2006; Chen et al. 2008a ).
FUTURE PERSPECTIVES
The structural studies have provided the molecular bases for several major signaling events in FGF signaling, including FGF-FGFR specificity, HS-assisted FGF-FGFR dimerization, and FGFR kinase regulation. Many imminent questions in the FGF field remain for structural biologists to address, however. Elucidation of the crystal structure of the endocrine FGF-FGFRKlotho ternary complex is a top priority, as it will provide a novel mechanism by which FGF-FGFR dimerization is achieved. Crystal structures with a representative from the FGF4 and FGF9 subfamilies in complex with their cognate FGFR should complete our understanding of the molecular mechanisms governing the specificity/promiscuity of this complex system. At the intracellular level, future work should be directed toward obtaining additional structures of trans-phosphorylation events, especially of the A-loop tyrosine phosphorylation, the gatekeeping phosphorylation event. Crystal structures of downstream signaling substrates in complex with the intracellular kinase domain will undoubtedly yield valuable information on how FGFR substrates are docked onto the kinase and are phosphorylated. The crystallographic data indicate that intrinsic protein dynamics may also modulate the activity of both the extracellular domain and intracellular domains of FGFRs (Chen et al. 2007; Kalinina et al. 2012) . Ideally, the crystallographic snapshots should be complemented by NMR dynamic studies and computational methods to provide a more accurate four-dimensional perspective of FGF signaling. These structural data will be valuable in directing future biochemical interrogations of this complex signaling network, and provide a framework for a comprehensive understanding of the basis of disease and structure-based drug discovery for many human diseases where perturbed FGF signaling is implicated.
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